Northern Trust’s Xenetic Biosciences XBIO Stock Holding History

Northern Trust’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,776	Closed	-$7.21K	–	4591
2023 Q1	$7.21K	Hold	1,776	–	–	﹤0.01%	4550
2022 Q4	$5.06K	Hold	1,776	–	–	﹤0.01%	4627
2022 Q3	$10K	Hold	1,776	–	–	﹤0.01%	4643
2022 Q2	$14K	Hold	1,776	–	–	﹤0.01%	4669
2022 Q1	$18K	Hold	1,776	–	–	﹤0.01%	4677
2021 Q4	$23K	Hold	1,776	–	–	﹤0.01%	4699
2021 Q3	$36K	Buy	+1,776	New	+$48.4K	﹤0.01%	4574

Other funds holding XBIO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.35B AUM 34.37% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust's XBIO Position: Q2 2023 in Review

Northern Trust sold out of Xenetic Biosciences (XBIO) in Q2 2023, closing a stake of 1,776 shares — an estimated $7.21K sold.

Northern Trust first reported a position in XBIO in Q3 2021 and held it in 7 quarters. The position peaked at $36K in Q3 2021. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2023.

Northern Trust reported no remaining Xenetic Biosciences position as of Q2 2023 after selling out during the quarter.
Northern Trust sold 1,776 Xenetic Biosciences shares in Q2 2023, an estimated $7.21K.
Northern Trust first reported a position in Xenetic Biosciences in Q3 2021 and held it in 7 quarters.
Northern Trust's Xenetic Biosciences position peaked at $36K in Q3 2021.
9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2023.

Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.